Search

Displaying results 2111 - 2120 of 2453 in total
  1. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  2. Drug

    Arketamine

    go.drugbank.com/drugs/DB19150
    Investigational

    Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  3. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

    Categories: Substance P, antagonists & inhibitorsSynonyms: Substance P, Neurokinin p
  4. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Sorbitan monolaurate

    go.drugbank.com/drugs/DB20157
    Investigational

    Sorbitan monolaurate is a small molecule drug. Sorbitan monolaurate has a monoisotopic molecular weight of 346.24 Da.

    Categories: P-glycoprotein inhibitors
  6. Drug

    Imnopitant

    go.drugbank.com/drugs/DB21456
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Imnopitant is a neurokinin NK1​ (substance P) receptor antagonist. Imnopitant has a monoisotopic molecular weight of 550.22 Da.

  7. Drug

    Zastaprazan

    go.drugbank.com/drugs/DB21524
    Investigational

    Zastaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. Zastaprazan is under investigation in clinical trial NCT058148...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Limnetrelvir

    go.drugbank.com/drugs/DB21677
    Experimental

    Limnetrelvir is a small molecule drug. The usage of the INN stem '-trelvir' in the name indicates that Limnetrelvir is a antiviral 3CL protease inhibitor. Limnetrelvir has a monoisotopic molecular weight of 557.17 Da.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Enerisant

    go.drugbank.com/drugs/DB20605
    Experimental

    Enerisant is a small molecule drug. The usage of the INN stem '-isant' in the name indicates that Enerisant is a histamine H3​ receptor antagonist. Enerisant has a monoisotopic molecular weight of 398.23 Da.

    Categories: P-glycoprotein substrates
  10. Drug

    Besigomsin

    go.drugbank.com/drugs/DB20894
    Experimental

    Besigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates